Clarithromycin laurate salt: physicochemical properties and pharmacokinetics after oral administration in humans

References

• Alkhalidi BA, Al-Ghazawi M, AlKhatib HS, Sallam A. 2010. Development of a predictive in vitro dissolution for clarithromycin granular suspension based on in vitro-in vivo correlations. Pharm Dev Technol. 15:286–295.
   PubMed Web of Science ®Google Scholar
• Amsden GW. 1996. Erythromycin, clarithromycin, and azithromycin: are the differences real? Clin Ther. 18: 56–72.
   PubMed Web of Science ®Google Scholar
• Aungst BJ, Hussain MA. 1992. Sustained propranolol delivery and increased oral bioavailability in dogs given a propranolol laurate salt. Pharm Res. 9:1507–1509.
   PubMed Web of Science ®Google Scholar
• Cannon JB, Adeyinka WN, Papp KJ. 1995. Reduction of pain on intravenous infusion with bile salt formulations for a macrolide antibiotic. Int J Pharm. 114:65–74.
   Google Scholar
• Dawber JG, Shaw JMA. 1989. A nuclear magnetic resonance and molecular-modelling study of cyclohexylamine and several N-substituted derivatives and their hydrochloride salts. J Chem Soc, Perkin Trans 2. 9:1249–1254.
   Google Scholar
• Forner K, Holm R, Morakul B, Junyaprasert VB, Ackermann M, Mazur J, Langguth P. 2017. Dissolution and dissolution/permeation experiments for predicting systemic exposure following oral administration of the BCS class II drug clarithromycin. Eur J Pharm Sci. 101:211–219.
   PubMed Web of Science ®Google Scholar
• Fujiki S, Iwao Y, Kobayashi M, Miyagishima A, Itai S. 2011. Stabilization mechanism of clarithromycin tablets under gastric pH conditions. Chem Pharm Bull. 59:553–558.
   PubMed Web of Science ®Google Scholar
• Green PG, Hadgraft J. 1987. Facilitated transfer of cationic drugs across a lipoidal membrane by oleic acid and lauric acid. Int J Pharm. 37:251–255.
   Web of Science ®Google Scholar
• [ICH] The International Council for Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human U. 2016. E6 (R2) Integrated addendum to ICH E6 (R1): guideline for good clinical practice. [Accessed 2018 July 12] http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R1_Guideline.pdf.
   Google Scholar
• Ishii K, Saito Y, Itai S, Nemoto M, Takayama K, Nagai T. 1998. Comparative study of pharmacokinetic parameters between clarithromycin and erythromycin stearate in relation to their physicochemical properties. Drug Dev Ind Pharm. 24:129–137.
   PubMed Web of Science ®Google Scholar
• Labes D, Schuetz H, Lang B. 2017. R package Power TOST: Power and sample size based on two one-sided t-tests (TOST) for (bio) equivalence studies. Retrieved from: http://www.r-project.org
   Google Scholar
• Lee Y-C, Dalton C, Regler B, Harris D. 2018. Drug solubility in fatty acids as a formulation design approach for lipid-based formulations: a technical note. Drug Dev Ind Pharm. 44:1551–1556.
   PubMed Web of Science ®Google Scholar
• Li S, He H, Parthiban LJ, Yin H, Serajuddin AT. 2005. IV-IVC considerations in the development of immediate-release oral dosage form. J Pharm Sci. 94:1396–1417.
   PubMed Web of Science ®Google Scholar
• Maggio B, Lucy JA. 1975. Studies on mixed monolayers of phospholipids and fusogenic lipids. Biochem J. 149:597–608.
   PubMed Web of Science ®Google Scholar
• McFarland JW, Berger CM, Froshauer SA, Hayashi SF, Hecker SJ, Jaynes BH, Jefson MR, Kamicker BJ, Lipinski CA, Lundy KM, et al. 1997. Quantitative structure-activity relationships among macrolide antibacterial agents: in vitro and in vivo potency against Pasteurella multocida. J Med Chem. 40:1340.
   PubMed Web of Science ®Google Scholar
• Morakul B, Suksiriworapong J, Chomnawang MT, Langguth P, Junyaprasert VB. 2014. Dissolution enhancement and in vitro performance of clarithromycin nanocrystals produced by precipitation-lyophilization-homogenization method. Eur J Pharm Biopharm. 88:886–896.
   PubMed Web of Science ®Google Scholar
• Mordi MN, Pelta MD, Boote V, Morris GA, Barber J. 2000. Acid-catalyzed degradation of clarithromycin and erythromycin B: a comparative study using NMR spectroscopy. J Med Chem. 43:467–474.
   PubMed Web of Science ®Google Scholar
• Morimoto S, Misawa Y, Asaka T, Kondoh H, Watanabe Y. 1990. Chemical modification of erythromycins. VI. Structure and antibacterial activity of acid degradation products of 6-O-methylerythromycins A. J Antibiot. 43:570–573.
   PubMed Web of Science ®Google Scholar
• Morimoto S, Takahashi Y, Watanabe Y, Omura S. 1984. Chemical modification of erythromycins. I. Synthesis and antibacterial activity of 6-O-methylerythromycins A. J Antibiot. 37:187–189.
   PubMed Web of Science ®Google Scholar
• Muranishi S. 1985. Modification of intestinal absorption of drugs by lipoidal adjuvants. Pharm Res. 2:108–118.
   PubMedGoogle Scholar
• Nakagawa Y, Itai S, Yoshida T, Nagai T. 1992. Physicochemical properties and stability in the acidic solution of a new macrolide antibiotic, clarithromycin, in comparison with erythromycin. Chem Pharm Bull. 40:725–728.
   PubMed Web of Science ®Google Scholar
• Noguchi S, Takiyama K, Fujiki S, Iwao Y, Miura K, Itai S. 2014. Polymorphic transformation of antibiotic clarithromycin under acidic condition. J Pharm Sci. 103:580–586.
   PubMed Web of Science ®Google Scholar
• [OECD] The Organisation for Economic Co-operation and Development series on principles of good laboratory practice and compliance monitoring. 1997. Number 1 – OECD principles on good laboratory practice.[accessed 2018 July 12] http://www.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=env/mc/chem%2898%2917&doclanguage=en.
   Google Scholar
• Peterson WL, Graham DY, Marshall B, Blaser MJ, Genta RM, Klein PD, Stratton CW, Drnec J, Prokocimer P, Siepman N. 1993. Clarithromycin as monotherapy for eradication of Helicobacter pylori: a randomized, double-blind trial. Am J Gastroenterol. 88:1860–1864.
   PubMed Web of Science ®Google Scholar
• R Core Team. 2017. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing. https://www.R-project.org/ Accessed July 12th, 2018.
   Google Scholar
• Rezhdo O, Speciner L, Carrier R. 2016. Lipid associated oral delivery: mechanism and analysis of oral absorption enhancement. J Control Release. 240:544–560.
   PubMed Web of Science ®Google Scholar
• Salem II. 1996. Analytical profiles of drug substances and excipients. Clarithromycin. San Diego: Academic Press. 24: 45–50
   Google Scholar
• Suwa T, Yoshida H, Fukushima K, Nagate T. 1988. Metabolic fate of TE-031 (A-56268) III. Absorption, distribution and excretion of 14C-TE -0341 in rats, mice and dogs. Chemotherapy. 36:213–226.
   Google Scholar
• Wadhwa H. 2003. Controlled release macrolide pharmaceutical formulations, U.S. patent 20030077325 A1.
   Google Scholar
• [WMA] World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects; 2013. [accessed 2018 July 12] https://www.wma.net/wp-content/uploads/2016/11/DoH-Oct2013-JAMA.pdf.
   Google Scholar
• Zhang XR, Zhang YF, Wang J, Zhou HB, Li SM, Zhong DF. 2008. Pharmacokinetics of clarithromycin citrate salt after oral administration to beagle dogs and food effects on its absorption. PDA J Pharm Sci Technol. 62:445–453.
   PubMedGoogle Scholar